Company Story

Founded in 2011 by Australian MedTech entrepreneur Jim Manolios, Haemokinesis® is transforming blood grouping.

Headquartered in Melbourne, Australia, with a production and distribution facility in Switzerland, Haemokinesis® is led by a team of leading Australian clinical diagnostics experts. Together they have spent the last decade creating innovative solutions in blood grouping and emergency medicine.

Haemokinesis® researches, develops and manufactures products which provide results to medical professionals in clinically relevant timeframes.

Our innovative point-of-care diagnostics, semi-automated and automated analysers streamline testing and analysis. Each has been created closely with healthcare professionals to close the gaps present in laboratories, hospitals and wherever testing is needed.

Haemokinesis® has a growing global presence across the world already including Africa, Asia-Pacific, Europe, Middle East and North and South America via direct sales and distributor networks.


At Haemokinesis®, we deliver advanced blood diagnostic and testing technology that’s safe, fast, accurate and reliable.

We are solving the challenges of point-of-care (POC) / point-of-trauma blood diagnostics and the limitations of existing blood testing in hospitals and blood banks. We speed up and simplify diagnostic testing and analysis for medical professionals to improve patient outcomes and help save lives.


Haemokinesis® is committed to removing the barriers of access to the basic elements of healthcare around the world. Focused on blood group testing and emergency medicine. Haemokinesis® provides safe and timely blood group testing as a fundamental requirement of a healthcare system and innovative point-of-care solutions in emergency medicine, the Company’s vision is to ensure anyone, anywhere has access to vital diagnostic technology.

Path of innovation

Haemokinesis journey begins!

Haemokinesis® established by entrepreneur CEO Jim Manolios on 27th Sept 2011.

Development of STARGEL10 & STATUS1

Innovation led by Jim Manolios, STARGEL10® & STATUS1® was successfully created and the World’s fastest Gel test was born in 2012.

ISO 9001:2008 Certification

Setting up a new company from the ground up was no easy task and the team at Haemokinesis® were successful at receiving ISO 9001:2008 accreditation in 2013.

ISO 13485 accreditation

Haemokinesis® staff achieved the ISO 13485 medical device certification in 2018.

Swiss facility acquired

2018 saw the acquisition of DAYmedical SA in Switzerland.

DAYmate S machine Launch

2018 also saw the launch of the Haemokinesis® updated DAYmate S machine.

CE Mark for STARGEL10® & STATUS1®

June 2018 Haemokinesis® receives CE mark certification for its STARGEL10® and STATUS1® instruments and consumables.

GLIF One Minute Group test Launched

A collaboration with Monash University saw the development of a paper based blood grouping test. Super fast, easy to use, and no instrumentation needed. 2019 the GLIF card test was launched.

STARGEL10 & STATUS1 approved by TGA

TGA approves Haemokinesis’ STARGEL10® and STATUS1® products in 2019 for the Australian market.

Eclipse automate launched

January 2020 sees the launch of the Haemokinesis® high throughput analyser, Haemokinesis Eclipse®, for STARGEL10® applications. Redefining expectations of a large laboratory analyser, in terms of speed, capacity, throughput, STAT management and productivity.


Our Senior Leaders at Haemokinesis® bring extensive expertise and experience in healthcare, pharmaceuticals using their talents to grow and innovate the blood diagnostic sector.


Jim Manolios

Chief Executive Officer and Managing Director

Jim Manolios is the Managing Director of Haemokinesis and founding the company in 2011, bringing more than 37 years in diagnostics pathology and 30 years in Blood Banking to the company along with substantial experience in gel manufacturing, instrument automation and biochemistry.

Jim previously co-founded DiaMedAustralia and Lateral Grifols B, along with other companies specialising in immunohaematology products with production sites in Australia.


Dr Alex Abrahams


Non-Executive Director

Dr Alex Abrahams, a Non-Executive Director at Haemokinesis and brings substantial experience in the dentistry and corporate health sector. He was a founder and major shareholder of Pacific Smiles Ltd (ASX.PSQ) and now retired as a Non-Executive Director

Alex is also a Non-Executive Director of MicroEquities Asset Management Ltd (ASX.MAM), major shareholder and Executive Chairman of Group Homes Australia Pty Ltd (unlisted).


Lou Panaccio

Non-Executive Director

Lou Panaccio is the Non-Executive Director at Haemokinesis and brings extensive experience working in corporate healthcare in senior management positions including as the Chairman of Health Networks Australia and the CEO of Melbourne Pathology.

He is currently a non-executive Director of ASX listed companies Sonic Healthcare Ltd (SHL.ASX), Avita Therapeutics, Inc (AVH.ASX) and Rhythm Biosciences Ltd (RHY.ASX). He is also the Non-Executive Director of Unison Housing Ltd.


Debbie Ormsby

Non-Executive Director

Ms Ormsby is a senior executive with over 25 years’ experience across the pharmaceutical and biotech industries both domestically and globally.

Prior corporate roles include ANZ Country Head and General Manager of The Medicines Company (acquired by Novartis), ANZ Country Head and Managing Director of Meda Pharmaceuticals, APAC Regional Medical Director of Actelion Pharmaceuticals (acquired by Janssen), Global Study Leader at Roche Products Ltd (UK) and Chief Commercial Officer of THC Global (THC.ASX).

Ms Ormsby has a cross-functional background with extensive experience in strategy development and implementation including leadership of start-up organisations, go-to-market strategies and end to end product commercialisation. Her career spans highly specialised medical markets with a particular emphasis on haematology, virology and cardiovascular. She is a registered pharmacist and is currently Director, Commercialisation at The Heart Research Institute.


Michael Ohanessian

Non-Executive Director

Michael Bernard Ohanessian is the Non-Executive Director at Haemokinesis and brings extensive experience gained from technology-related businesses with a mixture of operational, strategic and leadership capabilities. Following a ten-year career at Mobil Oil, Michael joined the Boston Consulting Group where he consulted to clients in a wide range of industries which include banking, airlines, mining, packaging, sports, oil and gas, retailing and biotechnology.
Michael then became the CEO of Vision BioSystems (now Leica BioSystems) where he led a transformation over seven years into a globally successful medical diagnostics company. He has also served as CEO and Managing Director of ASX-listed Genetic Technologies Limited and has been involved in investment management and corporate advice with Lion Capital. Michael then joined ASX-listed Praemium Limited as its CEO and Managing Director from 2011 to 2021. Michael was a Non-Executive Director of the SGP Group of Companies (now Trajan) and has been a Non-Executive Director of ASX-listed Bluechiip since 2014.



Jim Manolios

Chief Executive Officer and Managing Director

Jim Manolios is the Managing Director of Haemokinesis and founding the company in 2011, bringing more than 37 years in diagnostics pathology and 30 years in Blood Banking to the company along with substantial experience in gel manufacturing, instrument automation and biochemistry.

Jim previously co-founded DiaMedAustralia and Lateral Grifols B, along with other companies specialising in immunohaematology products with production sites in Australia.


Dr Sanjeev Alfred


Chief Commercial Officer

Sanjeev joined Haemokinesis in April 2021. Sanjeev has substantial experience in the immunohaematology and clinical diagnostics sector joining us, from Bio-Rad Laboratories (BIO:NYSE). Sanjeev was previously the Regional Manager (South Pacific Region), Clinical Diagnostics Group at Bio-Rad and prior to that was the Regional Marketing Manager (Asia-Pacific) at Thermo Fisher Scientific (TMO:NYSE).

Sanjeev has more than 15 years of experience in the Life Science and Clinical diagnostic markets. Furthermore, he has significant experience in establishing distributors and large-scale distributor networks. Sanjeev holds a PhD (Biological Sciences) from the University of Sydney along with an Executive MBA from the Australian Catholic University. He is also a member of the Australian Institute of Company directors.


Conn Pasakos

Chief Financial Officer

Conn Pasakos was appointed as the Chief Financial Officer for Haemokinesis in September 2020 and has more than 30 years commercial experience including senior finance positions across manufacturing wholesale distribution and IT&T. Conn has previously worked in senior accounting and financial advisory roles at PwC and Deloitte.



Siobhan McAndrew

Production Manager

Siobhan joined Haemokinesis in 2012 as Production Manager soon after Haemokinesis was established. Siobhan has over 16 years’ experience in the Immunohaemolatology Industry starting her career with Dia-Med Australia before moving on to Lateral Grifols. She moved from Ireland to Australia in 2004 after completing a 4 years honours degree in Bachelor of Science, majoring in Industrial Microbiology from University College Dublin (UCD).

During her career she has worked on Research, Design and Production of Diagnostic reagents. Siobhan has brought her knowledge and skill into the product development of Haemokinesis reagent portfolio and is committed to producing products of a high quality standard.


Mark Benson

Applications and Service Manager

Mark has over 40 years’ experience in the clinical diagnostics sector. Prior to joining Haemokinesis in June 2016, Mark has held many senior technical support roles at Beckman Coulter, DiaMed and Grifols.


Raoul Cadei

Instrument & Software Operating Officer

Raoul has been involved with Haemokinesis since 2014, where he was in charge of software development before joining the company in 2018, when he became COO and implemented software and instrument production improvements. Raoul’s extensive experience, including IT knowledge, saw him work as a consultant for some of the most important companies in Italy and abroad: the Italian Automobile Club (ACI), Publitalia’80 (Mediaset Group) and other top International Motorsport Federations.

In more than 25 years, Raoul learned to master many different technologies, particularly focused on the development of complex and functional product management architectures. His passion for streamlining industry and processes brought him to become a certified Six Sigma Black Belt, with also a certification in Scrum Agile project management.


Armin Köchli

Global Marketing Manager

In August 2018, Armin joined Haemokinesis as Global Sales and Marketing Manager. Previously, Armin was at DiaMed for 17 years and Bio-Rad as a Division Marketing Manager. Armin has extensive knowledge and experience in the immunohaematology field.

Armin was previously the Division Marketing Manager at Bio-Rad for the Immunohaematology Division and has introduced new automated solutions to the market as well as several new blood grouping tests. Armin has more than 25 years experience in the Clinical diagnostic market. Armin started his career as a bio-medical scientist and later studied for Master in Marketing in Bern, Switzerland.